Skip to main content
SpringerLink
Log in

Immunosuppression: Have We Learnt Anything

  • Chapter
  • First Online:
Essentials in Lung Transplantation

  • 810 Accesses

Abstract

Effective immunosuppressive medications are the cornerstone of successful solid organ transplantation. This chapter examines current drug regimens used in Australia and internationally in lung transplantation and the evidence for their use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACR:

Acute rejection/acute cellular rejection

ATG:

Anti-thymocyte globulin

BOS:

Bronchiolitis obliterans syndrome

C0:

Trough drug level

C2:

Drug level taken 2 h post dose

CLAD:

Chronic allograft dysfunction

CNI:

Calcineurin inhibitor

FEV1:

Forced expiratory volume in 1 s

IL-2:

Interleukin 2

ISHLT :

International Society for Heart and Lung Transplantation

MHC:

Major histocompatibility complex

MMF:

Mycophenolate mofetil

mTOR:

Mammalian target of rapamycin

SD:

Standard deviation

TDM:

Therapeutic drug monitoring

UNOS:

United Network for Organ Sharing

References

  1. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–75.

    Article  CAS  PubMed  Google Scholar 

  2. Chambers DC, Yusen RD, Cherikh WS, Goldfarb SB, Kucheryavaya AY, Khusch K, Levvey BJ, Lund LH, Meiser B, Rossano JW, Stehlik J, International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36:1047–59.

    Article  PubMed  Google Scholar 

  3. Mehra MR, Zucker MJ, Wagoner L, Michler R, Boehmer J, Kovarik J, Vasquez A. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant. 2005;24:1297–304.

    Article  PubMed  Google Scholar 

  4. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol. 1997;8:1771–7.

    PubMed  CAS  Google Scholar 

  5. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338:161–5.

    Article  CAS  PubMed  Google Scholar 

  6. Whitson BA, Lehman A, Wehr A, Hayes D Jr, Kirkby S, Pope-Harman A, Kilic A, Higgins RS. To induce or not to induce: a 21st century evaluation of lung transplant immunosuppression's effect on survival. Clin Transpl. 2014;28:450–61.

    Article  CAS  Google Scholar 

  7. Furuya Y, Jayarajan SN, Taghavi S, Cordova FC, Patel N, Shiose A, Leotta E, Criner GJ, Guy TS, Wheatley GH, Kaiser LR, Toyoda Y. The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients. Am J Transplant. 2016;16:2334–41.

    Article  CAS  PubMed  Google Scholar 

  8. Snell GI, Westall GP, Levvey BJ, Jaksch P, Keshavjee S, Hoopes CW, Ahya V, Mehta A, Trulock EP 3rd. A randomized, double-blind, placebo-controlled, multicenter study of rabbit ATG in the prophylaxis of acute rejection in lung transplantation. Am J Transplant. 2014;14:1191–8.

    Article  CAS  PubMed  Google Scholar 

  9. Hartwig MG, Snyder LD, Appel JZ 3rd, Cantu E 3rd, Lin SS, Palmer SM, Davis RD. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant. 2008;27:547–53.

    Article  PubMed  Google Scholar 

  10. Palmer SM, Miralles AP, Lawrence CM, Gaynor JW, Davis RD, Tapson VF. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest. 1999;116:127–33.

    Article  CAS  PubMed  Google Scholar 

  11. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. The registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012;31:1073–86.

    Article  PubMed  Google Scholar 

  12. Swarup R, Allenspach LL, Nemeh HW, Stagner LD, Betensley AD. Timing of basiliximab induction and development of acute rejection in lung transplant patients. J Heart Lung Transplant. 2011;30:1228–35.

    Article  PubMed  Google Scholar 

  13. Hachem RR, Chakinala MM, Yusen RD, Lynch JP, Aloush AA, Patterson GA, Trulock EP. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant. 2005;24:1320–6.

    Article  PubMed  Google Scholar 

  14. Glanville AR, Aboyoun C, Klepetko W, Reichenspurner H, Treede H, Verschuuren EA, Boehler A, Benden C, Hopkins P, Corris PA, European and Australian Investigators in Lung Transplantation. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation. J Heart Lung Transplant. 2015;34:16–25.

    Article  PubMed  Google Scholar 

  15. Appel JZ 3rd, Hartwig MG, Davis RD, Reinsmoen NL. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol. 2005;66:378–86.

    Article  CAS  PubMed  Google Scholar 

  16. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, Hardesty RL, Weyant RJ, Griffith BP. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995;60:580–84; discussion 584-585.

    Article  CAS  PubMed  Google Scholar 

  17. Treede H, Klepetko W, Reichenspurner H, Zuckermann A, Meiser B, Birsan T, Wisser W, Reichert B. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant. 2001;20:511–7.

    Article  CAS  PubMed  Google Scholar 

  18. Treede H, Glanville AR, Klepetko W, Aboyoun C, Vettorazzi E, Lama R, Bravo C, Knoop C, Aubert JD, Reichenspurner H. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant. 2012;31:797–804.

    Article  PubMed  Google Scholar 

  19. Penninga L, Penninga EI, Moller CH, Iversen M, Steinbruchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013;5:CD008817. https://doi.org/10.1002/14651858.CD008817.pub2.

  20. Glanville AR, Aboyoun CL, Morton JM, Plit M, Malouf MA. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant. 2006;25:928–34.

    Article  PubMed  Google Scholar 

  21. Capone D, Tarantino G, Gentile A, Sabbatini M, Polichetti G, Santangelo M, Nappi R, Ciotola A, D’Alessandro V, Renda A, Basile V, Federico S. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther. 2010;35:121–4.

    Article  CAS  PubMed  Google Scholar 

  22. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997;63:39–47.

    Article  CAS  PubMed  Google Scholar 

  23. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507–15.

    Article  CAS  PubMed  Google Scholar 

  24. Glanville AR, Corris PA, McNeil KD, Wahlers T. Mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation for the prevention of bronchiolitis obliterans syndrome (BOS): results of a 3 year international randomised trial. J Heart Lung Transplant. 2003;22:S207.

    Article  Google Scholar 

  25. O’Hair DP, Cantu E, McGregor C, Jorgensen B, Gerow-Smith R, Galantowicz ME, Schulman LL. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant. 1998;17:864–8.

    PubMed  Google Scholar 

  26. Palmer SM, Baz MA, Sanders L, Miralles AP, Lawrence CM, Rea JB, Zander DS, Edwards LJ, Staples ED, Tapson VF, Davis RD. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation. 2001;71:1772–6.

    Article  CAS  PubMed  Google Scholar 

  27. Ross DJ, Waters PF, Levine M, Kramer M, Ruzevich S, Kass RM. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant. 1998;17:768–74.

    PubMed  CAS  Google Scholar 

  28. Zuckermann A, Birsan T, Thaghavi S, Artemiou O, Kupilik N, Dekan G, Wolner E, Klepetko W. Mycophenolate mofetil in lung transplantation. Transplant Proc. 1998;30:1514–6.

    Article  CAS  PubMed  Google Scholar 

  29. Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrancois N, Charpentier B, Quere S, Di Giambattista F, Cassuto E. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int. 2010;23:1084–93.

    Article  CAS  PubMed  Google Scholar 

  30. Snell GI, Valentine VG, Vitulo P, Glanville AR, McGiffin DC, Loyd JE, Roman A, Aris R, Sole A, Hmissi A, Pirron U. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant. 2006;6:169–77.

    Article  CAS  PubMed  Google Scholar 

  31. Vigano M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpon LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant. 2007;26:584–92.

    Article  PubMed  Google Scholar 

  32. Strueber M, Warnecke G, Fuge J, Simon AR, Zhang R, Welte T, Haverich A, Gottlieb J. Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial. Am J Transplant. 2016;16:3171–80.

    Article  CAS  PubMed  Google Scholar 

  33. King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation. 2003;75:1437–43.

    Article  PubMed  Google Scholar 

  34. Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant. 2005;24:1863–7.

    Article  PubMed  Google Scholar 

  35. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation. 2006;82:1153–62.

    Article  PubMed  Google Scholar 

  36. Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjortuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation. 2010;89:864–72.

    Article  CAS  PubMed  Google Scholar 

  37. Villanueva J, Boukhamseen A, Bhorade SM. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J Heart Lung Transplant. 2005;24:421–5.

    Article  PubMed  Google Scholar 

  38. Shitrit D, Rahamimov R, Gidon S, Bakal I, Bargil-Shitrit A, Milton S, Kramer MR. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. Kidney Int. 2005;67:1471–5.

    Article  CAS  PubMed  Google Scholar 

  39. Ghassemieh B, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Alex CG, Bag R, Deoliveira NC, Vigneswaran WT, Charbeneau J, Garrity ER, Bhorade SM. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant. 2013;32:701–6.

    Article  PubMed  Google Scholar 

  40. Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11:2453–62.

    Article  CAS  PubMed  Google Scholar 

  41. Vigano M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis. 2010;12:23–30.

    Article  CAS  PubMed  Google Scholar 

  42. Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int. 2017;91:954–63.

    Article  CAS  PubMed  Google Scholar 

  43. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581–9.

    Article  CAS  PubMed  Google Scholar 

  44. Caroti L, Zanazzi M, Paudice N, Tsalouchos A, Carta P, Larti A, Pimpinelli N, Moscarelli L, Salvadori M, Bertoni E. Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin. Transplant Proc. 2012;44:1926–7.

    Article  CAS  PubMed  Google Scholar 

  45. Vos R, Vanaudenaerde BM, Ottevaere A, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Wauters S, Van Raemdonck DE, Nawrot TS, Dupont LJ, Verleden GM. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant. 2010;29:1358–68.

    Article  PubMed  Google Scholar 

  46. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, Schoonis A, Nawrot TS, Dupont LJ, Verleden GM. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J. 2011;37:164–72.

    Article  CAS  PubMed  Google Scholar 

  47. Jain R, Hachem RR, Morrell MR, Trulock EP, Chakinala MM, Yusen RD, Huang HJ, Mohanakumar T, Patterson GA, Walter MJ. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2010;29:531–7.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, Solomon M, McCrindle BW, Grant D. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14:968–75.

    Article  PubMed  Google Scholar 

  49. Shemesh E, Fine RN. Is calculating the standard deviation of tacrolimus blood levels the new gold standard for evaluating non-adherence to medications in transplant recipients? Pediatr Transplant. 2010;14:940–3.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Venkat VL, Nick TG, Wang Y, Bucuvalas JC. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence. Pediatr Transplant. 2008;12:67–72.

    Article  PubMed  Google Scholar 

  51. Chiang CY, Schneider HG, Levvey B, Mitchell L, Snell GI. Tacrolimus level variability is a novel measure associated with increased acute rejection in lung transplant (LTx) recipients. J Heart Lung Transplant. 2013;32:S170.

    Article  Google Scholar 

  52. Kurnatowska I, Krawczyk J, Oleksik T, Nowicki M. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. Transplant Proc. 2011;43:2954–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia

    Miranda Paraskeva

Authors
  1. Miranda Paraskeva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miranda Paraskeva .

Editor information

Editors and Affiliations

  1. The Lung Transplant Unit, Department of Thoracic Medicine, St Vincent’s Hospital, Sydney, NSW, Australia

    Allan R. Glanville

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Paraskeva, M. (2019). Immunosuppression: Have We Learnt Anything. In: Glanville, A. (eds) Essentials in Lung Transplantation . Springer, Cham. https://doi.org/10.1007/978-3-319-90933-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90933-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90932-5

  • Online ISBN: 978-3-319-90933-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation